Osteoporosis is a degenerative skeletal disease with a limited number of treatment options. CK2.3， a novel peptide， may be a potential therapeutic. It induces osteogenesis and bone formation in vitro and in vivo by acting downstream of BMPRIA through releasing CK2 from the receptor. However， the detailed signaling pathways， the time frame of signaling， and genes activated remain largely unknown.
Osteoporosis is a degenerative skeletal disease with a limited number of treatment options. CK2.3， a novel peptide， may be a potential therapeutic. It induces osteogenesis and bone formation in vitro and in vivo by acting downstream of BMPRIA through releasing CK2 from the receptor. However， the detailed signaling pathways， the time frame of signaling， and genes activated remain largely unknown.
